

Table A3. Atezolizumab Efficacy by TC2 or IC2 Programmed Death-Ligand 1 Status					
Cohort	No. of Patients	ORR, No. (%; 95% CI)*	Median DOR, Months (95% CI)	Median PFS, Months (95% CI)*	Median OS, Months (95% CI)
1	74	10 (14; 6 to 23)	5.6 (4.6 to NE)	5.3 (2.8 to 6.9)	20.1 (NE to NE)
2	146	20 (14; 9 to 20)	11.3 (6.9 to NE)	2.6 (1.4 to 2.8)	15.5 (11.9 to NE)
3	136	14 (10; 6 to 17)	11.8 (8.4 to NE)	2.7 (1.5 to 2.8)	11.0 (7.5 to 14.9)

NOTE. On the basis of a data cutoff of December 1, 2015. TC2/3 or IC2/3 excluding TC3 or IC3.  
Abbreviations: DOR, duration of response; IC, tumor-infiltrating immune cells; IC2 =  $\geq$  5% and < 10%; PFS, progression-free survival; NE, not estimable; ORR, objective response rate; OS, overall survival; TC, tumor cells; TC2 =  $\geq$  5% and < 50%; TC2/3 or IC2/3 = TC or IC  $\geq$  5% PD-L1-expressing cells, respectively; TC3 or IC3 = TC  $\geq$  50% or IC  $\geq$  10% PD-L1-expressing cells, respectively.  
\*Assessed by an independent review facility per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

Table A3. Atezolizumab Efficacy by TC2 or IC2 Programmed Death-Ligand 1 Status